Neurocrine Biosciences, Inc. (NBIX) Earnings Call Transcript
July 30, 2026
Earnings Call Speaker Segments
Good Thursday to all of you, and welcome to the Neurocrine Biosciences call covering our second-quarter 2026 results. Joining me on this call today are Kyle Gano, our Chief Executive Officer; Matt Abernethy, our Chief Financial Officer; Eric Benevich, our Chief Commercial Officer; Sanjay Keswani, our Chief Medical Officer; and Samir Siddhanti, who is joining in his well-deserved new position as Chief Business Officer. We'll be making forward-looking statements on today's call; those statements carry certain risks and uncertainties, and our actual results could differ materially. Please take a look at the risk factors covered in our most recent SEC filings. Also, a portion of the information we discuss today consists of non-GAAP financial measures that were not calculated in accordance with U.S. GAAP. You'll find reconciliations of those non-GAAP financial measures to the most directly comparable GAAP financial measures in the tables at the end of our earnings release, which went out earlier today and is now available on the Investor Relations page of Neurocrine's website. Once we finish our prepared remarks, we'll move into Q&A; at this point I'll pass the call to Kyle.
Thanks, Todd, and good afternoon, everybody. The results Neurocrine posted for the second quarter show what a diversified growth strategy designed to compound over time can do. With net product sales above $950 million, our commercial portfolio of first-in-class medicines — INGREZZA, CRENESSITY and VYKAT XR — produced yet another record quarter, allowing more patients to gain access to our innovative medicines; that durable commercial performance gives us the financial strength to keep investing in innovation, move our industry-leading pipeline forward and chase strategic opportunities that make Neurocrine even stronger for long-term growth. Our strategy hasn't changed: run our commercial portfolio so our medicines reach patients, push our innovation engine ahead and deploy capital with discipline. Across all 3 of those priorities, this quarter showed meaningful progress. Durable growth keeps coming from the commercial business. One of the industry's strongest mid- to late-stage portfolios is advancing in the pipeline; and the successful acquisition and integration of VYKAT XR showed disciplined capital deployment. Taken together, these efforts strengthen our position in rare disease even further while extending our leadership in endocrinology. Even more important, these results showed how Neurocrine keeps evolving. Only a few years back, most people saw us as a company with a single product. Now we have multiple commercial growth drivers, a pipeline expanding across every phase of development and the financial strength to invest through innovation cycles. Those strengths together put us in position to build long-term value for patients, physicians, employees and shareholders alike. Going forward, we're still on track for multiple important clinical milestones in 2027, among them Phase III data readouts for osavampator in major depressive disorder and direclidine in schizophrenia. Along with the ongoing integration of VYKAT XR, those milestones mark the next chapter of Neurocrine's growth and bolster our confidence in the opportunity that lies ahead. Before handing the call to Matt, I want to acknowledge Samir Siddhanti on his recent promotion to Chief Business Officer. Samir has been instrumental in shaping our corporate strategy and business development efforts since he joined Neurocrine in 2017. As part of our executive leadership team, he'll help steer the next phase of Neurocrine's growth and evolution. Samir, congratulations; we're excited for what's ahead; and with that, I'll hand the call over to Matt.
Good afternoon, everyone. In Q2, total revenue came in above $950 million, which works out to almost 40% growth compared with the prior-year period. That figure includes a full quarter of contributions from INGREZZA and CRENESSITY, plus a partial quarter from VYKAT XR after the Soleno acquisition closed. These results show top line growth that is speeding up, and they produced a financial profile with non-GAAP EPS of $2.85 per share. Let me begin with INGREZZA. Net sales for the second quarter reached $716 million, a 15% increase versus the prior-year quarter, powered by yet another period of record new patient additions and steady underlying demand. On the strength of that showing, we are lifting our full year INGREZZA guidance from $2.7 billion to $2.8 billion, setting a new range of $2.825 billion to $2.875 billion. At the midpoint, that amounts to roughly 13% growth over the prior year. For CRENESSITY, second quarter net sales totaled $184 million, which speaks to continued strong launch execution, steady new patient starts and widening prescriber adoption. Roughly 15% of the estimated diagnosed patient population has now received a CRENESSITY prescription, which strengthens our confidence in the substantial runway for growth. Now to VYKAT XR. Pro forma net sales in the second quarter were $94 million, and Neurocrine recognized $54 million of that from May 18, the date the Soleno acquisition closed. Integration has moved along well, and we expect to drive sequential quarterly growth as we exit 2026. New patient demand stayed fairly consistent with the first quarter, while discontinuation rates came in line with what we anticipated after the initial launch bolus in 2025; there is more work ahead of us in developing this market, and we remain optimistic about the opportunity to help many more patients with PWS in the years to come. Pro forma total revenues for the second quarter of 2026 reached $998 million when full quarter VYKAT XR sales are included. These results underscore the strength and growing scale of our commercial portfolio across 3 highly differentiated products. Now to our financials. With the Soleno acquisition closed, I want to briefly cover the financial impact of the deal, including the purchase accounting and the GAAP to non-GAAP adjustments shown in our earnings release. We bought Soleno for about $2.9 billion and funded the transaction with cash on hand; we finished the second quarter with roughly $500 million in cash and no debt. Both strategically and financially, this acquisition is highly attractive. VYKAT XR brings another differentiated, durable growth product into our portfolio and is immediately accretive to non-GAAP earnings. As a result, we updated operating expense guidance to reflect the Soleno operating expenses, transaction and integration costs and the expected purchase accounting intangible and inventory fair value amortization impacts for the rest of 2026; we expect approximately $150 million of acquisition-related costs, with $130 million of that recognized in the second quarter. Our GAAP second quarter results also include noncash purchase accounting amortization of acquired intangible assets and inventory fair value step-up of approximately $20 million. Taking everything into account, our commercial portfolio keeps delivering outstanding results, bringing in nearly $1 billion in pro forma quarterly sales, which gives us considerable financial flexibility to invest in line with our capital allocation priorities — fueling revenue growth, moving our expanding pipeline forward, and chasing further strategic business development opportunities. Thanks to rising sales, a strengthening financial profile, and significant data catalysts on the horizon, we consider ourselves very lucky to be in a position where we can keep building a leading global biotech company. Having said that, I'll turn things over now to Eric Benevich, our Chief Commercial Officer. Eric?
Thank you, Matt. Only 5 years back, Neurocrine was a commercial-stage business built on one product, marking INGREZZA's rise to blockbuster status after crossing $1 billion in yearly sales. As of today, we market 3 first-in-class therapies, and their combined quarterly revenue is nearing $1 billion, which annualizes to roughly $4 billion. That shift shows our long-term growth plan is being executed successfully. Beginning with INGREZZA, the second quarter was exceptional, posting record revenue of $716 million, powered by yet another period of all-time peaks in both new patient starts and total prescriptions. Given our raised full year guidance, we anticipate serving more patients than at any point previously among those dealing with tardive dyskinesia or chorea tied to Huntington's disease. CRENESSITY likewise turned in another superb sales quarter, bringing in $184 million. This launch keeps displaying a highly consistent pattern: a steady cadence of new patient starts, strong persistence and compliance, plus favorable reimbursement. Adoption stays balanced between adults and pediatric patients, male and female patients, and throughout the business segments of CAH Centers of Excellence, pediatric endocrinologists and community adult endocrinologists. Significantly, our prescriber base is now nearly 3 times what it was 1 year ago, giving us a solid foundation for further growth. Moving to VYKAT XR. Though we are still very early in folding this franchise into our commercial platform, second quarter trends left us encouraged. New patient starts held steady sequentially. The prescriber base kept growing, and discontinuations stayed in line with expectations after the initial bolus of patients who started therapy last year. Like any acquisition, full integration will require a few quarters. And we're eager to bring Neurocrine's commercial, medical and patient support capabilities to the VYKAT team and the PWS community. We stay confident about driving sequential growth as we exit 2026 and maintain our conviction that VYKAT XR could become the third blockbuster in our portfolio. Before I close, I want to offer a special thank you to our commercial and medical teams in neuropsychiatry and rare endocrinology, our internal cross-functional colleagues and the VYKAT XR team from Soleno. Q2 was a quarter of major transformative change for Neurocrine, in which we both broadened our existing commercial footprint to better serve the needs of health care providers and patients, while we also started integrating VYKAT XR into our company. We carried out all these significant structural changes without missing a beat in our mission to help more patients. My hat is literally off to our teams for achieving such a tremendous transformation while at the same time delivering such a strong quarter. Now I'll hand the call over to our Chief Medical Officer, Dr. Sanjay Keswani.
Thank you, Eric, and hello everybody this afternoon. My remarks today will start with the key takeaways from ENDO 2026, where we shared significant new findings covering both CRENESSITY and VYKAT XR. To begin with CRENESSITY, we shared 2-year results from the continuing CAHtalyst open-label trials involving pediatric and adult subjects who have classic congenital adrenal hyperplasia; such findings showed meaningful and lasting gains in several areas of health, among them cardiometabolic outcomes, bone health, quality of life and pediatric growth, while further confirming CRENESSITY's favorable long-term safety profile; regarding VYKAT XR, we shared 3-year HQ-CT and Prader-Willi syndrome profile results that compared treated subjects against a natural history cohort. Such analyses showed substantial and sustained decreases in hyperphagia at every time point assessed, backing up the durability of the treatment benefit. Further results additionally revealed meaningful gains when subjects who had stopped therapy earlier began treatment again, emphasizing how important it is to keep treating in order to sustain long-term outcomes. Taken together, these findings reinforce the expanding evidence base behind both CRENESSITY and VYKAT XR and underscore the meaningful difference these medicines are making for patients and the endocrinology community. Now shifting to the pipeline. We keep making consistent headway. In particular, we are still set to report Phase III top line results for osavampator in major depressive disorder during the second half of 2027. We are also still set to report the first Phase III readout for direclidine in schizophrenia during the second half of 2027, and for the second Phase III study in 2028. Looking forward, we are excited to host our neurology and immunology webinar in early December, where we will give an update on our strategy and spotlight key programs spanning both therapeutic areas. With that, I'll give the call back to Todd.
Excellent. Chloe, let's jump into Q&A.
Nice work on the strong quarter and on getting it done. About INGREZZA — at this point in the year, how clear a picture do you have regarding pricing trends for next year? Also, what are you hearing, or what insight are you gaining, when it comes to access trends now that the AUSTEDO MFP is in effect?
Paul, Kyle here. Appreciate the question. Perhaps to begin with where things stand for 2026 — access has been excellent this year, with roughly 70% of all Medicare lives covered through the contracting we put in place last year, and as we look at the back half of 2026, we anticipate that pricing will stay fairly steady from one year to the next. When it comes to 2027, clearly our talks with payers are happening right now, and we ought to have a read on that before this year ends. But I believe where we sit today is that we do observe a process, and the route ahead involves not only us but other players too, such that MFP adjacent products will have a place for Medicare beneficiaries. And when you combine that with the reality that we hold the leading position in this VMAT2 category, there will be plenty of opportunity for us to secure the same access we currently have going forward — robust access through '27 and '28; so at the moment, it's entirely about extracting whatever we can with our team. I'd be doing a disservice if I didn't point out that this market as a whole keeps expanding at a double-digit rate from one year to the next. So plenty of runway remains in this market, and that's where our focus will stay.
Kyle, do you have any sense of how much more it could cost to keep this access in place next year or further out?
Paul, I'd say it's premature for us to make a determination on that. We'll be in a position to say more about it later in the year. As things stand, we've had an excellent first half, and we'll keep building on the momentum we've observed.
Our question concerns CRENESSITY, which had a very robust quarter, with revenue climbing 20% versus the prior quarter. From what was said in the prepared remarks, it seems like things were consistent throughout. So patient additions were steady, reimbursement was solid, and there was no bolus. I'd like to know if that reading is accurate. Did Q2 contain any one-time items that drove such particular strength and that we ought not to project into the second half of the year? Or should we consider this rate of revenue expansion typical for the coming two quarters?
Yes. In my view, describing Q2 really amounts to a continuation of what we observed earlier in the launch, a highly steady and reliable cadence of new patients being added. Adoption keeps showing up in every segment we are targeting. The pediatric endocrinologists, the adult community endocrinologists and those Centers of Excellence. We're genuinely pleased that our estimate now puts roughly 15% of the addressable patient population on treatment, and we definitely anticipate continued robust momentum going forward.
My question concerns VYKAT. This quarter's $94 million in results is basically level compared to the prior period. You've only recently assumed leadership of this franchise. Could you perhaps describe a few of the steps you're taking to speed up the launch trajectory, now that you have full control of the franchise? And perhaps offer a few details on actions you're taking that you believe might show an impact within a quarter or 2?
Sure, Tazeen. Let me begin by noting that what we delivered in Q2 matched what we anticipated when we came out of diligence. I'd certainly say we continue to learn quite a bit regarding the hyperphagia market opportunity. What we've discovered up to now only strengthens our convictions regarding this medicine's potential to be a blockbuster; and we remain deep within our integration process at this point. Still, in the end, I believe the fundamentals are what count, continuing to find patients so we can introduce VYKAT XR to the providers who care for them, mainly in endocrinology, and then offer solid education and guidance on selecting suitable patients, on assisting them through titration and on reaching good outcomes; so I feel quite positive about what's possible with VYKAT. Everything physicians with experience using it have told me has been very favorable, and I certainly look forward to continuing to drive this product's launch, which remains very early in its commercial ramp.
And Tazeen, Kyle here. As we discuss VYKAT XR, I keep in mind that this marks the first earnings call since the deal closed where we've actually talked about it. So I want to raise what makes the acquisition, and the product, worthwhile. For us, there's an excellent strategic and financial match. VYKAT XR treats Prader-Willi syndrome as a first-in-class, first-in-disease therapy, which places it in the very same category we witnessed with INGREZZA and CRENESSITY at the time they launched. That strategic alignment has us genuinely enthusiastic. Clearly, we can keep building out our endocrinology franchise going forward. Yet because this product joins the Neurocrine umbrella early in its launch, we not only get to serve many thousands of patients under Neurocrine, which is thrilling, we also capture the financial upside of maximizing all the revenue growth landing on our top line, plus diversification. So a lot of financial alignment exists too, and beyond that, we believe the IP estate extends into the mid-2040s. That makes it durable as well. All in all, we're quite enthusiastic about what sits before us. I think Eric highlighted several of the items we're now examining, and we're eager to push this into the same blockbuster category that we observe for CRENESSITY and INGREZZA going forward.
The sole point I would make is that this matched what we had anticipated internally. We understood the asset we were acquiring, and there is a huge opportunity here to assist a much larger number of patients. As a result, we hold a great deal of confidence in the team, the product, and the chance to support many additional patients with PWS; so we feel encouraged as we look ahead.
Nice work on a strong quarter. Let me hop in with something about VYKAT too. Back in the Soleno era, folks argued quite a bit about how new start boluses differ from dropouts, roughly speaking, and now that you're wrapping your head around the picture, could you describe what you're observing — specifically, to what extent are those initial bolus figures actually driving the dropout rate we're seeing today? Also, should we anticipate some upward equilibrium between new starts and dropout rates in quarters ahead?
Yes. Thanks for asking; Kyle here. From what we've observed regarding new patient starts, the flow has been fairly consistent across the last couple of quarters, which is encouraging. That lines up well with what we anticipated once our diligence on the company wrapped up. On discontinuations, clearly, given the bolus of patients at launch, some of those are still working their way through as time passes, yet we anticipate the final rate landing where other orphan medicines sit, somewhere in the 25% to 30% range. That's the figure we'll be watching going forward. Still, our aim ultimately is sequential growth as we close out 2026 and into subsequent years, so at present we're exactly where we ought to be. Perhaps more significantly, I'm genuinely thrilled to watch our team deliver its resources and backing to the Soleno team, now part of the Neurocrine brand, and combine everyone's learnings so this medicine becomes the finest it can be going forward.
Nice work on a strong quarter. I'd like to get a clearer picture of your VYKAT remarks for the coming quarters. You're indicating that when it comes to new patients starting, the expectation is stability. So I'm curious — does that mean revenue might swing around somewhat? At the same time, what you seem to be saying is that by the time 2026 comes to a close, you have confidence about generating sequential growth. I'm just trying to figure out how you'd describe the upcoming quarters while you fold the business into your own operations.
Yes. Moving from Q3 into Q4, we'd expect to see some sequential growth. Then, when you look ahead to next year, momentum is really the key thing. Yet, as we've discussed, you have that combination of new patient additions being partially canceled out by discontinuations, and our sense is that the bolus of discontinuations will be behind us in this quarter. So, as we've stated, we'd expect to be sequential growers in Q4 and beyond.
I'm curious about the reactions physicians have had to the 2-year CRENESSITY information covering both adults and peds. And in what ways might that information influence how much the product gets taken up?
Appreciate it, Anupam. We're genuinely happy with what doctors are telling us regarding the 2-year results we shared not long ago at ENDO. Notably, that encompassed data from adults as well as pediatric patients and showed benefits over the long term when it comes to lowering androgens and reducing glucocorticoid steroids too. So that response has us truly thrilled. On top of that, this comes alongside a safety-tolerability profile that looks quite good. Notably, as of now, exposure has reached more than 35,000 patient weeks. That matters a great deal once more, given how broad the population is that we treat with CRENESSITY.
With the latest purchase of a possible upcoming rival in CAH, could you discuss the clinical strategy and expected schedules for your next-gen CRENESSITY products, insofar as those are required to protect the franchise down the road?
Sure. I appreciate that question. Our next-generation treatment is presently in clinical development. It is NBIP-01435, a protein-based therapeutic peptide we are working on, which would be given once a week or less often for patients who want that specific choice of not needing to be concerned with daily dosing. Beyond that, it might provide extra benefits as well, thanks to the PK profile. Thus, we have excellent Phase I results so far from this program, and we are eager to launch a Phase II trial soon and deliver it to patients as fast as possible. Returning to CRENESSITY briefly, I would note that it has established a very high standard. It has strong efficacy, strong safety, strong tolerability, and what a remarkable label we managed to secure from the clinical program; we have several formulations and a broad range of ages covered by the medicine. And as Sanjay just said, we now have several years of clinical evidence to rely upon, plus a multi-year lead. I mention this because such a high standard not only makes things harder for rivals, but also for our very own clinical portfolio programs. So we are truly thrilled about where we stand today with CRENESSITY. There is still plenty of space to expand; roughly 15% of the market is currently being treated with CRENESSITY, and we will keep increasing that over time until it becomes the standard of care for patients.
Nice work on the quarter, and congratulations to Samir. What we want to ask about concerns what lies ahead for your psychiatry franchise, given that data readouts for osavampator and direclidine are anticipated next year. Is the commercial infrastructure already in place that you'd want for launching those 2 products? Or perhaps, what's your thinking on how to build out that organization?
Thank you, Jay; the way I'd describe it is that for a future infrastructure needed for osavampator, direclidine, or both, we have a genuinely solid base. As you're aware, we currently have a sizable footprint in psychiatry and in long-term care, plus a very strong reputation among those provider communities. Looking at the profile of either of those 2 medicines, we might need to strengthen our teams or carry out some reorganization efforts, yet I believe we're positioned quite well when it comes to drawing on our existing foundation. And you might remember that last fall, when we discussed the planned expansion of our INGREZZA team, we noted that this expansion's value was both to speed up growth of our INGREZZA business and to position us favorably for upcoming launches of our Phase III psychiatry assets. So near-term changes to our footprint aren't something I expect. Still, I certainly think we're well positioned to speed up those adjustments to our commercial platform once we're past positive Phase III data.
In my view, that would be a wonderful day, especially if OSA comes back positive, when you consider moving into primary care and being in a position to assist patients dealing with major depressive disorder. Achieving that would mean an increase in overall spending on SG&A around 2028 and 2029. Still, I believe you'd share my view that all of us would take great pleasure in having the opportunity to do that. For now, though, our attention is on delivering results, as Eric put it, with INGREZZA, and on further broadening the difference we're making throughout the psychiatry community at present.
I've got a handful of things to ask about what you're doing in obesity. First, regarding 2118, the CRF2 asset — once you're in obese patients, what are you anticipating in your Phase I trial for monotherapy in terms of weight reduction and keeping muscle intact? Then, about 1968, your GGG — is that in the clinic already? It surprises me that you can kick off a combo study with the CRF2 this year when there's no monotherapy data yet. And last, thinking about the combo, do you have any idea when the first complete dataset from that would be available?
I really appreciate those questions. When it comes to our CRF2 agonist, we're clearly quite enthusiastic about this molecule. It's the first obesity molecule of ours to reach the clinic. Phase I data are being gathered right now, and next year we're slated to have a readout from a signal-seeking study covering both weight reduction and preservation of lean mass, so that's genuinely exciting for us. Whether I'll say anything about the specific bar we're targeting, I'm not certain. Still, it's clear we want a robust effect, not only for weight loss, as I mentioned, but for preserving muscle mass as well; behind CRF2 we have additional molecules in our obesity portfolio that will be entering the clinic before long.
What's your thinking on the capacity to even out both top and bottom line growth as we move through 2029, the year the IRA gets implemented for INGREZZA? And the response to that hinges simply on the Phase III readouts you'll have next year. Under the different pipeline scenarios, how do you anticipate that unfolding?
Thanks, Josh. Kyle here. Clearly, we're watching closely how our MFP plays out with the IRA. Those talks get underway next year. And of course, as soon as we know which MFP would be applied to INGREZZA in 2029, everyone will be brought up to speed. But at a high level, what we're seeing as our commercial portfolio evolves are medicines that are also expanding across that period. So our belief is we'll wind up in a solid spot there, with top line revenue continuing to grow through the close of this decade and past it. Where earnings are concerned — or rather, on the income side, or the expense side, of the equation — Phase III trials of ours will also be sunsetting across that same stretch within our pipeline, which shifts more toward an earlier mid-stage type — pipeline, sorry. And my sense is that's more or less a look into a steady state portfolio by the time we reach the end of this decade. And it all ties back to what we laid out at the start of this year regarding expectations for new Phase I, Phase II and Phase III starts. So I'm pleased with what we have as a company and how we've set it up, and over the coming couple of years, as 2029 draws nearer, we'll keep people informed.
Yeah. How much EPS moves around will mostly come down to, like you mentioned, what happens once the IRA kicks in during 2029. On the cost side, though, like I said before, if osavampator turns out positive, we're going to put money out ahead of revenue to get that sales team built up in that market. So you'll probably see investments come in waves, and that could create some ups and downs in earnings, but growing revenue over the long haul is our North Star. And from those investments, I think we'll see really solid earnings growth as you look out toward the 2030s.
For CRENESSITY, it looks like you're experiencing quite impressive expansion in the prescriber base. What I'm wondering is this: among the practices you're targeting, what share hasn't started using CRENESSITY whatsoever? At this point in the launch, what barriers remain for those practices? And what's your plan for getting past them?
Yeah, that's a good question. How I'd put it is that every quarter we're adding a really solid number of new prescribers, and at this point we're what I'd describe as still early in the commercial ramp overall. So there's plenty of runway ahead. The reason I hedged my remarks slightly is that as our understanding of this market deepens, along with the opportunity we have to find patients, our target list does shift somewhat as practices move on and off it. Still, on the whole, what we've heard back has been extremely favorable. Among the doctors who've given CRENESSITY a try, most have only put one patient on it so far, and I believe that comes down to 2 factors. First is how patients arrive at their practices — particularly among adults, a patient might show up just once per year, so if a doctor has multiple patients, it takes time to get them all in. Second is what we refer to as this market's long tail. Not many practices actually have more than a small number of patients, while a great many physician practices have just 1 or 2. So in the end, we're quite pleased with the growth we've recorded, and we've discussed this very steady, consistent pace we're maintaining. I see that as largely a reflection of our patient finding work and, naturally, our team's execution.
My question concerns how CRENESSITY is performing at launch. You continue to comfortably exceed our figures. I'm curious about how this drug is doing relative to what you anticipated internally. Is it matching those expectations? If that's the case, at what point will you feel ready to provide guidance, assuming it's surpassing what you expected internally? Which main areas are driving that?
I'd say it's fairly aligned with what we expected internally; that being said, every quarter we're gaining a huge amount of knowledge. From the start of the launch, the input we've received from clinicians has been really encouraging, and the strong persistency rates have also been impressive. We're observing many of the advantages and hearing clinicians report on the longer-term results and the value there; so we remain at a very early stage of launch, just 6 quarters in. It's too soon for us to consider offering a more formal guide. That said, our internal models are moving nearer to the figures we're producing, yet still, I'd tell the team, continue over-delivering; they've accomplished something amazing bringing a new product to market for the first time in more than 70 years and there's so much learning happening and so much enthusiasm; so praise to the team, excellent work. And we'll tackle the guidance aspect of your question as we move further into the year toward next year.
Yeah. About VYKAT, Matt, I simply want to confirm I've got this right. Are you indicating that in 3Q we ought to anticipate revenue at approximately the identical level as 2Q, and after that 4Q ought to demonstrate a bit of sequential expansion compared with 3Q? And that's driven by this gating matter, this timing matter, whatever term you prefer, involving people stopping treatment from the bolus that happened, let's say roughly 6 months back, or thereabouts, something along those lines; and then, if I may, one more thing. I'm just wondering how the R&D team views any takeaways from the MapLight data that came out earlier this week.
Yeah. On VYKAT, I believe your phrasing was right, though I'd step back and note that we've possessed this product for merely 6 weeks; and it's a market that we've — we couldn't be more thrilled about. We're getting fantastic input from clinicians as well. So like you mentioned, this is largely a matter of working past a portion of the bolus of discontinuations and afterward putting into practice a few of the items Eric described when it comes to helping more patients with their PWS. So regarding expectations, I think your description matches what I was attempting to convey.
I'll address the MapLight question now. Perhaps the best way to begin is by picking up where Matt stopped regarding VYKAT. I simply want everyone to fully recognize that an integration of this company is currently underway; and clearly, some disruption is natural while you move through that process, much like what happens during a sales force expansion; however, as all of you are aware, we possess considerable expertise when it comes to expanding sales forces, having done so with INGREZZA and CRENESSITY, and each time we emerged on the far side in a far better position, and our belief is that VYKAT will follow that same pattern. Regarding MapLight, their data did appear within the last 2 days. To my mind, that represents a solid piece of evidence that further confirms the orthosteric strategy behind employing a muscarinic agonist, even though what they are doing differs completely from what we are doing, and those distinctions deserve to be highlighted. Much like Cobenfy, the approved drug that relies upon the muscarinic pathway. The MapLight method likewise needs a muscarinic antagonist added back in order to control adverse events. With direclidine, ours is the sole method — our first-in-class method — employing a selective M4 agonist that functions perfectly well on its own. Nothing needs to be added back to reduce side effects. Still, we understand that ultimately, efficacy is what gets you through the door. Victory actually comes from how you perform on the remaining dimensions, such as safety and tolerability, such as how simple the drug is to administer, and that is precisely where direclidine will truly stand out. In our Phase II trial, what we observed was an extremely clean GI profile, no weight gain, no food effect, once a day, no titration. That is the path to winning here, exactly as we have witnessed with other antipsychotics spanning the range from low to high efficacy. Every one of them succeeded on safety, tolerability and ease of administration.
Let's turn to VYKAT. Could you break down what portion of the discontinuations stem from edema? And on the edema management side, what steps will you take to assist patients and practitioners in handling it, so that fluid retention leads to fewer people stopping treatment?
Sure, Kyle here. My sense is we won't dive into what those discontinuations looked like specifically. That said, as with any drug — particularly one you're taking over, bringing in — there's always room to sharpen messaging and education. I'm aware that will be a major focus for our team. That education and messaging is consistent, once more, throughout every medicine we evaluate, for caregivers, patients and physicians. With VYKAT XR, clearly, consider even a basic element like how it's dosed; it calls for a titration schedule driven by weight. That stands out. So you need to make sure you can properly educate around it, and also establish the correct efficacy expectations. This isn't a painkiller where you feel better the day you start taking it. Hyperphagia improvement can require months. So all of that is what we're actively working through, and we'll keep partnering with the team to reach a strong position as we aim to fully welcome the Soleno team into Neurocrine and build on insights from both sides to deliver the best for patients.
Turning to CRENESSITY, I'd like your take on the competition in this space. Vertex bought atumelnant, and they pointed out 7 LFT elevation cases, whereas Crinetics had previously disclosed 2 cases — yet Vertex still paid a pretty hefty premium. From where you sit, what do you believe was behind that? Does it tell you CAH could be a very big market? Or could it be that the LFT elevation isn't actually a problem at all?
Yes. Thanks for that, Ash. Commenting on a competitor, or any of the competitors in the spaces where we operate, is really difficult for us. What I can tell you is how excited we are about our own medicine. Let me point back to the CAHtalyst data — our 2-year data, 35,000 patient weeks of exposure, still building over time — showing that at the 2-year mark, 70% of patients were receiving a physiological dose of a GC, and 70% of patients had a physiological concentration of their androgens. That's a pretty good place to be for CAH, and honestly for any medicine. As time goes on, we'll keep hopefully building more data of that kind and type to demonstrate the real benefits for patients.
Nice work on the quarter. I was hoping to get your perspective regarding the peak opportunity for CRENESSITY. Would you still call that product a blockbuster prospect? I'm asking since a recent acquisition appears to have your rivals claiming it could be a $3 billion market or even bigger. And you're already at the better part of $0.75 billion on an annualized basis; plus, Eric, you mentioned that you're truly at an early stage of the launch; so I'm curious if a blockbuster drug is the correct frame for this, or whether that multibillion dollar type of assertion from the competitive acquisition is the more pertinent one here.
Myles, we're going to aim for the largest figure we can achieve and assist as many patients as we can. I believe you put it very nicely. The trajectory up to now has been incredibly, incredibly robust, very pleasing, and I think it shows the significant unmet need in the market, the excellent product we've got, and the excellent team as well. If you look historically at other rare disease launches of this kind, peak penetration lands somewhere between 30% and 50% for chronic type medicines. So if you consider what the peak opportunity is, that's the ZIP code. I realize that's quite a wide range, and we're going to strive to reach as high within it as we can; but yes, you can arrive at a really attractive figure fairly quickly; yet ultimately it comes down to concentrating on assisting as many patients as possible for their CAH.
I'd like to ask something about the pipeline. This is just a brief follow-up. With how Cobenfy has been performing and what we've been hearing back, I'm interested in your perspective regarding the opportunity for the muscarinic approach, and perhaps you could also describe your broader strategy for developing the muscarinic franchise, since you may have several products that target various indications.
Thank you, Rudy. Samir speaking. I'm very grateful for that question about the muscarinic space. We currently have 4 chances to succeed within our muscarinic franchise, direclidine NBI-'568, which is presently in Phase III for treating schizophrenia and Phase II for bipolar — a Phase II trial is underway right now in bipolar mania. From a timeline standpoint, every study stays on track. Then there's the next-generation NBI-'570, an M4 compound that prefers the M1/M4 dual approach. It's currently in a Phase II trial for treating schizophrenia, and the opportunity we see is a possible long-acting injectable; this category of drugs has driven substantial commercial sales for other businesses, and in our view this is the sole possible LAI in the muscarinic field. NBI-'569 is at an earlier point, also an M1/M4 dual that we're examining in an early — a study in Alzheimer's disease. The idea there is to advance it into Alzheimer's disease psychosis; and we also have a fourth compound, NBI-'567, for which a Phase II trial in Alzheimer's cognition will begin shortly. Taken together, we believe we hold a best-in-class muscarinic franchise. We're eager to receive the direclidine data next year and proceed from that point.
One more point I'd make there: every one of these is an orthosteric agonist, so no add-back is needed in order to block side effects; they act selectively at M1 and M4. That makes them distinctive on that front, and it places us in a genuinely unique position within the muscarinic space.
The question I have is somewhat strategic in nature, and it carries financial consequences over the long term. Looking at every commercial product you currently have, there has usually been some element of being first to commercialize it, with initial approvals for the indications in question. Your pipeline, though, points to — it contains candidates in big markets where multiple products already exist, and where the rivals tend to be far bigger companies too. So might you offer any goals for what a steady-state, longer-horizon operating margin target could resemble for Neurocrine as you grow substantially bigger yourself?
Yes. I'll have Kyle address, and then Samir — pardon me, the strategic side of how we intend to compete with bigger players in those markets. I'd add, though, that Eric and the team have accomplished a tremendous amount in developing markets, and we feel we can stack up very well with medicines such as the muscarinics and the osavampator as well. Long-term operating margin guidance isn't something we'll provide, yet it's clear we're turning into a rather profitable company, with non-GAAP operating income exceeding 30%. So my sense is that what we're concentrated on at present is putting money into SG&A to expand sales to the greatest extent possible, and likewise to push the pipeline forward and reach those opportunities where we're able to compete in a number of the bigger markets where we think we can come out on top.
And maybe I should just jump in here — this is Kyle. If you look at it strategically, what we're really doing is building the pipeline so that we have a portfolio of medicines that are not just first-in-class but best-in-class, spanning neurology, psychiatry, endocrinology, and immunology too. Those are spaces where we believe we can compete, and we can do it in several different ways — whether that's through the molecules we design ourselves or, in the end, by owning specific mechanisms that nobody else has, that are unique to Neurocrine. Obesity came up on this call as one example, and we think we're out in front in that category with a CRF2 agonist, which is pretty novel. And obviously, we understand a great deal about the biology, since it's the biology the company was founded on. So in the end, what this approach accomplishes is that it spreads our risk across multiple therapeutic areas. We're grateful for all the psychiatry programs we have, and we think every one of them is a winner. But we're also aware that you don't get the complete picture on those assets until you're past Phase IIIs. We offset that by having a presence in some of the bigger disease states, obesity being one, where biomarkers exist, where endpoints are objective, and where we can actually get a read on the data from Phase Ib studies. So on balance, I'd say we've genuinely evened out the portfolio, and we've got the ability to swing for some big wins in some larger opportunities while also remaining within our wheelhouse of the more traditional neuropsych programs that you're accustomed to seeing from us. All told, though, this positions the company very nicely for the long term.
Following up about CRENESSITY — you highlighted very strong expansion in the prescriber base, but could you speak to how repeat prescribing is trending? On your earlier call, I believe you mentioned that about 2/3 of prescribers had written just one prescription. Are current prescribers starting to treat additional patients? Or is the growth mainly still coming from bringing on new prescribers? And looking ahead, where's the larger opportunity — broadening the prescriber footprint or deepening penetration among those already on board?
I'd describe it as somewhat of a mix when it comes to depth versus breadth. Every quarter we continue to bring in a meaningful number of new prescribers. And so far, the majority of prescribers who've tried CRENESSITY have treated only 1 or 2 patients. This market, though, is an inch deep and a mile wide — meaning few practices have more than a handful of classic CAH patients. Meanwhile, many CAH patients are out in the community, and plenty of the physicians treating them may have just one patient. So I expect we'll keep seeing this pattern of many physicians with only 1 or 2 patients under treatment. But at this point in the launch — essentially only about 1.5 years in — we're still witnessing considerable adoption from new prescribers. And we believe there's room to grow when it comes to building that prescriber base over time.
Nice work on a solid quarter. Here's my question — I was wondering something about CRENESSITY. When it comes to the rare subtypes, in particular those 11 beta-hydroxylase patients, where do things stand regarding how far along you are in getting payers to cover that subtype? That's something I'd like to know. Then, briefly on VYKAT, is there anything you can say about the strategy outside the U.S.? And how does that rank in terms of your relative priorities for that asset?
Let me just emphasize that coverage and reimbursement for CRENESSITY have been outstanding and have truly surpassed what we expected right from launch's earliest days. On the coverage side, what's generally needed — this being a specialty medicine — is that the physician completes a prior authorization. Usually, they must attest that the patient has classic CAH, typically without specifying which particular subtype, which genetic subtype, they have, that they are aged 4 years or older, and that they are presently taking glucocorticoids. Those are the coverage criteria for the great majority of patients. And claim approval rates have been really high. We've observed that claims generally get approved quite fast; and that it's very affordable for patients, with most patients, in fact more than 90%, paying $10 or less each month. So the reimbursement side is really strong.
Absolutely. When it comes to VYKAT XR outside the U.S., the top thing on our list at this moment is getting the team fully integrated and ensuring we do all we can for patients here in the U.S. now that we have approval. You might remember that during the transaction's closing process, Soleno pulled the EMA filing from review. So my sense is that after we've wrapped our arms around the integration, finished it, and pushed the medicine ahead here, we'll return to and take another look at what's possible in markets beyond the U.S. In the interim, for Europe, every patient who is on VYKAT XR today will keep going with their treatment, and we'll explore certain named patient program style mechanisms to support patients who might be seeking access in that area.
Regarding the Friedreich's ataxia program, what specifics can you give us about the Phase I readout expected in 2027 — which tissue compartments will be reporting frataxin protein levels, whether buccal cells, skin, or muscle? Also, what would you consider proof of mechanism? And will clinical results be reported as well, alongside the biomarker data?
No, I appreciate that question. Everyone here at Neurocrine is enthusiastic about the Friedreich's ataxia gene therapy program. Clinical development is set to begin later this year. Once that study is underway, we'll be anticipating actual patient data around the end of next year. As for the nature of what gets shared, I think that's something we'll settle over the next couple of months and into the beginning of the year; and with luck, we'll offer additional commentary at our R&D Day in December.
Nice work on the quarter. I wanted to ask whether you have any feedback or updated thinking regarding the competitive landscape and the risk posed by your rival in the VMAT inhibitor category. I believe your competitor also reported a really solid quarter. They've mentioned $3 billion in peak sales along with growing adoption of the AUSTEDO XR product. So when you look ahead over the coming years, and acknowledging there are some pricing dynamics at play, what's your view on how market share might shake out between 2 products? And will the pie keep expanding in TD, or will there be some share movement between the products?
Sure, I'll begin by noting that 10 years, nearly 10 years since INGREZZA launched, the TD market is still expanding quite quickly. We observe that a large number of patients remain untreated and even undiagnosed; therefore our emphasis stays on building awareness, increasing diagnosis and then, clearly, being in a position to inform providers about INGREZZA's distinctive advantages. And I think that — and clearly as well continuing to deliver robust reimbursement support. The results make the case on their own. INGREZZA has been the preferred and most prescribed VMAT2 inhibitor from day 1 and keeps holding that position. And even when we look at the latest quarter, with strong market growth for VMAT2s, INGREZZA grew faster than the market. So we can anticipate that this momentum will persist for the rest of this year. And as Kyle mentioned earlier, from a coverage and reimbursement standpoint, we anticipate solid coverage in '27 and '28 that will support continued strong growth when it comes to adoption. So all in all, we're very happy with our performance, and we'll let the results make the case on their own.
I'd like to discuss osavampator. Major depressive disorder is obviously a big market. You're quite excited about it. Just take us through what you're addressing that current antidepressant approaches don't handle well. And what would you need to demonstrate in a Phase III for this to genuinely be seen as differentiated instead of incremental?
Yes. Thanks for asking. For background, osavampator is an AMPA potentiator, and from a differentiation standpoint, we believe it offers distinct benefits compared with the current standard of care. Regarding efficacy, we anticipate stronger efficacy, especially among people who've already failed to respond, or responded poorly, to a wide range of other antidepressants with varying mechanisms of action. But second, and equally important, a very favorable safety and tolerability profile. In fact, one of the most striking aspects of our Phase II SAVITRI data was the safety and tolerability, and the implication is long-term adherence to this treatment.
We’re grateful to all of you for being here with us today. Your time and the good questions you’ve raised mean a lot to us, and we’re eager to keep talking with lots of you, of course at the investor conferences and meetings that will take place over the rest of the year. Before that, thank you once more for your backing and your interest, and enjoy the rest of your day. So long for now.
Thanks a lot. That wraps up the meeting for today. We’re grateful for your time and for joining in. You can go ahead and disconnect now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Neurocrine Biosciences, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Neurocrine Biosciences, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.